AVUV vs BSVO vs DFSV: Which Small-Cap Value ETF Is Best for DIY Investors?

Whether BSVO is a real challenger to AVUV in US small-cap value is a lively debate in factor investing. The reason it keeps coming up: AVUV has grown to roughly $28.6 billion by mid-2026, large enough that capacity becomes a fair question. In small-cap strategies, a big asset base can make it harder to trade illiquid names without moving prices or drifting toward larger stocks. Some investors now split their small-value sleeve across managers, holding both AVUV and BSVO, to diversify that risk.

It is a good question, and the usual answer you will find online is the wrong one. Most comparisons rank these funds by trailing return, which tells you what already happened, not what you are buying. What decides it is which process gives you the small-cap value exposure you want, at a cost and tracking-error profile you can hold through a decade when the strategy looks foolish. This guide compares AVUV, BSVO, and a third fund worth knowing, DFSV, on that basis.

Disclosure: I personally own AVUV and DFSV, and do not own BSVO. That reflects a preference for the two lower-cost, evidence-based options, not a claim that BSVO is a bad fund. This is educational, not individualized advice.

The three funds at a glance

Factor exposure is the real difference

AVUV is built around valuation theory with a profitability screen. Avantis frames expected return as a function of an asset’s price, its book equity, and its expected future profits, then tilts toward small-cap companies that are both cheap and more profitable. The tilts are visible in the fund’s own data: as of 3/31/2026, AVUV’s weighted-average book-to-market was 0.68x versus 0.56x for the Russell 2000 Value benchmark, and its weighted-average profits-to-book was 0.29x versus 0.11x.¹ It holds the value tilt and a profitability tilt roughly two and a half times the benchmark’s.

BSVO is a broader, deeper small-value fund. Bridgeway defines value using price-to-book, price-to-earnings, price-to-sales, and price-to-cash-flow, ranks small-cap stocks with a statistical evidence-based process, and weights roughly by market cap across a broad 600-to-700 stock “Omni” portfolio meant to approximate small-cap value as a whole.² It applies a light ESG tilt with a few narrow exclusions, not an ESG mandate. That broader, deeper-value reach shows up as heavier cyclical exposure: its recent fact sheet had financials around 33% of assets versus about 25% for the Russell 2000 Value Index, and energy near 18% versus about 10%.²

DFSV is Dimensional’s broad systematic version. It runs a similar evidence-based US small-value process across roughly 1,020 holdings, which makes it the most diversified of the three by name count and a close cousin of AVUV in spirit.

The clean way to hold these in your head: AVUV is small value with a quality screen, BSVO is deeper and junkier-cyclical small value, and DFSV is broad systematic small value sitting between them. That difference, not last year’s return, is what you are choosing.

Historical returns, read honestly

Over the shared five-year window through 5/31/2026, AVUV has led. AVUV returned roughly 11% annualized over five years on NAV, while BSVO returned about 9.6%.³ BSVO has surged more recently, up about 44% over the trailing year versus roughly 38% for AVUV, consistent with its deeper size and value tilt in a period that rewarded them.

Two cautions keep this fair. AVUV launched in September 2019, near an excellent stretch for small-cap value, and has no live ten-year record. BSVO’s ten-year and since-inception numbers are useful, but part of that history belongs to the predecessor Bridgeway Omni mutual fund (BOSVX), adopted when the strategy became an ETF in 2023.² Neither fund’s trailing numbers tell you which process is better from here.

What the academic evidence says

The case for small-cap value starts with Fama and French. Their 1992 work showed that size and book-to-market together captured the cross-section of average returns in their sample, and their 1993 model formalized market, size, and value as common equity factors.⁴⁵ Their 2015 five-factor model later added profitability and investment, and Novy-Marx showed that gross profitability predicts returns about as well as book-to-market does.⁶⁷

This is why AVUV’s profitability screen has intuitive appeal: small and cheap is not the same as good. Asness, Frazzini, Israel, Moskowitz, and Pedersen found that the size premium is weak and unstable on its own, but becomes much stronger and more reliable once you control for quality, or its inverse, junk.⁸ Buying the cheapest small stocks without regard to quality picks up distressed cyclicals and low-quality financials that are cheap for a reason. AVUV’s design tries to avoid that; BSVO’s deeper-value reach accepts more of it in exchange for stronger factor loadings.

Two honest caveats belong here. Fama and French themselves found that value (HML) becomes redundant for explaining average returns once profitability and investment are in the model, so “value” is not a settled standalone factor.⁶ And McLean and Pontiff documented that published return predictors earn about 26% less out-of-sample and 58% less after publication, as crowding and data-mining wear the edge down.⁹ The premia decay, though not to zero. Expect a smaller forward edge than the backtests imply, and long stretches where it disappears.

Is AVUV capacity-constrained or losing its edge?

Not on the current evidence, but it is worth watching. AVUV is no longer niche: around $28.6 billion in mid-2026, large for an active small-cap value ETF.¹⁰ Capacity is a legitimate concern, because a big book can force a small-cap fund toward larger, more liquid names and dilute its tilts.

The public data does not show that happening yet. As of 3/31/2026, AVUV’s weighted-average market cap was $3.7 billion, still slightly smaller than the Russell 2000 Value benchmark’s $3.8 billion, so the fund is not drifting up-cap. Its value spread (0.68x vs 0.56x book-to-market) and profitability spread (0.29x vs 0.11x) were both intact, and turnover stayed near 6%.¹ A single fact-sheet snapshot is not a decay study, but the metrics that would flag a capacity problem are not flashing.

If you want to monitor it yourself, watch four things across future fact sheets: weighted-average market cap rising relative to the benchmark, the book-to-market spread compressing, the profitability spread shrinking, and turnover or trading costs climbing. The McLean-Pontiff logic says a popular factor can fade; it does not say AVUV has faded. The honest read is that AVUV’s size makes capacity a watch item, not a demonstrated problem.

Risk and trading

All three funds can trail the S&P 500 and total-market funds for years. Value spent much of 2007 to 2020 out of favor, and small caps are more volatile and trade less easily than large caps. That is the bet: higher expected return in exchange for tracking error you have to stomach.

On trading, AVUV is the easiest of the three. It trades on the order of 1.2 to 1.6 million shares a day, while BSVO trades closer to 140,000, with a 30-day median bid-ask spread around 0.11%.³ BSVO’s spread is acceptable but its thinner volume rewards care. For any of these, use limit orders, and avoid trading in the first and last few minutes of the session, especially with BSVO.

Tax efficiency: AVUV vs DFSV vs BSVO

All three are far more tax-friendly than a traditional active mutual fund, because the ETF structure lets them push low-basis shares out through in-kind redemptions and keep turnover low, which reduces fund-level capital-gain distributions. In 2024, fewer than about 4% of ETFs paid any capital gains, versus roughly 64% of US equity mutual funds.¹¹ The wrapper does not make them tax-free: you still owe tax on dividends and on gains when you sell. It mainly spares you the surprise distributions that sting in a taxable account.

DFSV has the cleanest documented profile. Dimensional’s official 2025 figures show DFSV paid $0 in short-term and $0 in long-term capital gains, 0.00% of NAV, with 100% qualified dividend income.¹² BSVO is explicitly tax-managed (its predecessor was literally named a tax-managed fund), and its recent distribution history shows income distributions with no listed capital gains.³ AVUV is built for ETF tax efficiency too, with its very low turnover; it paid small capital gains in 2020 during its early, tiny-AUM period and has largely avoided them since. Confirm current-year qualified-dividend and distribution figures from each sponsor before relying on them in a taxable account.

DFSV also makes the best tax-loss-harvesting partner for AVUV. They are different issuers running different proprietary processes with different holdings, so they are generally treated as not substantially identical for wash-sale purposes, which lets you harvest a loss in one and rotate into the other without sitting out of the market. This is a gray area without an IRS bright-line rule for fund pairs, so treat it as general information, not tax advice.

What Larry Swedroe’s work says about structured funds

Larry Swedroe has long argued that structured, evidence-based funds can beat naive index funds, because they avoid the index reconstitution problems that let others front-run forced trades, and they screen out negative-momentum names, recent IPOs, and junky small-growth stocks that dilute factor exposure.¹³ His comparison of small-value funds across Vanguard, Dimensional, and Bridgeway traced their return differences mostly to different factor loadings rather than manager skill, and he stressed judging a fund on cost per unit of factor exposure rather than expense ratio alone.

That logic supports taking BSVO and its Bridgeway lineage seriously. It does not crown BSVO over AVUV or DFSV. Those articles analyzed the older Bridgeway Omni mutual fund, not today’s ETF lineup, and the point that deeper value loadings raise both expected return and tracking error cuts in every direction. These are Swedroe’s documented arguments for structured, deep-value funds, drawn from those specific articles. He remains active, and this guide does not represent his current view on AVUV, BSVO, or DFSV specifically. The modern question is no longer Bridgeway versus a plain index fund; it is Bridgeway versus Avantis versus Dimensional, and that is a much closer call where fees and tax efficiency matter more.

Can you actually hold it?

Treat small-cap value as a high-tracking-error bet that may raise your expected return, paid for by holding it through the years when it looks stupid. The calculator below sizes the two things you can plan for, the fee you pay and the dollar pain of a multi-year lag, so you can see whether a 10%, 20%, or 30% sleeve is something you could sit through without bailing at the bottom.

What I recommend

For most DIY investors building a US small-cap value sleeve, AVUV is the better default: the lowest fee, strong diversification, the best liquidity, and a profitability-aware design that maps cleanly to the evidence on size, value, and quality.

DFSV is the closest substitute and the cleanest tax-loss-harvesting partner for AVUV, with a similar process, a slightly higher fee, and a spotless tax record. BSVO is the deeper-value specialist: a fair choice for an investor who already understands factor investing, specifically wants a deeper small and cyclical value expression or manager diversification away from Avantis, and will trade carefully with limit orders despite the higher fee.

I would not hold AVUV and BSVO together without a specific reason, such as deliberate manager diversification or a tax-lot consideration. They are both US small-cap value. Holding both can feel diversified while economically doubling down on the same factor bet.

Who this is for, and who it is not

This comparison matters most if you are:

• Deciding how to implement a deliberate small-cap value tilt.
• Weighing AVUV’s size and capacity questions against alternatives.
• Harvesting losses and want a clean partner fund for a US small-value position.
• Holding small value in a taxable account and care about distributions.

It matters less if you do not want a small-value tilt at all. A total-market or S&P 500 index fund is a complete equity position on its own, and adding a tilt you cannot hold through a drought is worse than skipping it. If you are not sure you would stay the course, the honest move is a smaller sleeve or none.

Frequently Asked Questions

Is AVUV or BSVO better for small-cap value?

For most DIY investors, AVUV is the better default: it is cheaper (0.25% vs 0.45%), more liquid, and pairs its value tilt with a profitability screen the evidence supports. BSVO is a legitimate deeper-value alternative for investors who specifically want stronger size and value loadings or manager diversification and will trade it carefully.

Is AVUV too big or capacity-constrained?

At around $28.6 billion in mid-2026 it is large for an active small-cap value ETF, so capacity is a fair thing to watch. The current public data does not show a problem: AVUV’s weighted-average market cap is still smaller than its benchmark’s, and its value and profitability tilts are intact. Monitor the fund’s market-cap and factor spreads over time rather than assuming decay.

What is the difference between AVUV and DFSV?

Both are systematic US small-cap value ETFs with similar goals. AVUV (Avantis, 0.25%) holds about 799 stocks with an explicit profitability screen. DFSV (Dimensional, 0.30%) holds about 1,020 stocks and is a bit broader. They are close enough to be substitutes and different enough to serve as tax-loss-harvesting partners.

Is BSVO worth the higher expense ratio?

It can be, for the right investor. BSVO’s 0.45% fee buys a deeper, broader small-value implementation with heavier cyclical exposure and a long Bridgeway lineage. If you want that specific exposure or manager diversification, the fee may be justified. If you want the most efficient default, AVUV or DFSV is cheaper.

Are these funds tax-efficient enough for a taxable account?

Yes. All three use the ETF structure to minimize fund-level capital-gain distributions. DFSV has the cleanest documented 2025 record ($0 capital gains, 100% qualified dividend income), BSVO is explicitly tax-managed, and AVUV’s very low turnover has kept distributions minimal since 2020. You still owe tax on dividends and on gains when you sell.

Key Takeaways

• Pick the process, not the trailing return. The funds differ most in factor exposure, which is what you are buying.
• AVUV is the efficient default: lowest fee, best liquidity, value plus a profitability screen.
• DFSV is the closest substitute and the cleanest tax-loss-harvesting partner; BSVO is the deeper-value specialist.
• AVUV’s size is a watch item, not a problem yet. Its tilts are intact and its market cap is still below its benchmark.
• The hard part is holding it. Size the fee and the drawdown pain before you choose a sleeve you can keep through a drought.

Related Guides

• Concentration Risk: why a tilt should improve the whole portfolio, not just chase a factor.
• Four Signs of a Bubble: reading crowding and capacity without making a timing bet.
• An Index Fund Is Not a Financial Plan: where a small-value tilt fits, and where it does not.

Sources

1. Avantis U.S. Small Cap Value ETF (AVUV) Quarterly Fact Sheet, as of 3/31/2026 (book/market 0.68x vs 0.56x; profits/book 0.29x vs 0.11x; weighted-avg market cap $3.7B vs $3.8B benchmark). avantisinvestors.com.
2. EA Series Trust Prospectus (Oct 31, 2025), EA Bridgeway Omni Small-Cap Value ETF (BSVO): 0.45% fee, 600-700 issuer “Omni” portfolio, value metrics, ESG considerations, sector tilts, and predecessor BOSVX mutual-fund history (inception 12/31/2010, ETF reorganization March 2023). etfarchitect.com.
3. Bridgeway ETFs, BSVO fund page (NAV returns as of 5/31/2026, AUM ~$2.4B, 30-day median bid/ask spread 0.11%, distribution history, tax-management statement). bridgewayetfs.com.
4. Eugene F. Fama and Kenneth R. French, “The Cross-Section of Expected Stock Returns,” Journal of Finance 47(2), 1992. wiley.com.
5. Eugene F. Fama and Kenneth R. French, “Common Risk Factors in the Returns on Stocks and Bonds,” Journal of Financial Economics 33(1), 1993. sciencedirect.com.
6. Eugene F. Fama and Kenneth R. French, “A Five-Factor Asset Pricing Model,” Journal of Financial Economics 116(1), 2015 (adds profitability and investment; HML becomes redundant in the five-factor model). sciencedirect.com.
7. Robert Novy-Marx, “The Other Side of Value: The Gross Profitability Premium,” Journal of Financial Economics 108(1), 2013. sciencedirect.com.
8. Cliff Asness, Andrea Frazzini, Ronen Israel, Tobias Moskowitz, and Lasse Pedersen, “Size Matters, If You Control Your Junk,” Journal of Financial Economics 129(3), 2018. ssrn.com.
9. R. David McLean and Jeffrey Pontiff, “Does Academic Research Destroy Stock Return Predictability?” Journal of Finance 71(1), 2016 (~26% lower out-of-sample, ~58% lower post-publication). wiley.com.
10. AVUV fund data (AUM ~$28.6B, average volume, holdings, turnover), mid-2026. stockanalysis.com.
11. Morningstar, “Good News for ETF Investors: Capital Gains Distributions Remain Low” (2024: fewer than ~4% of ETFs distributed gains vs ~64% of US equity mutual funds). morningstar.com.
12. Dimensional, 2025 Capital Gain Distributions and Qualified Dividend Income (DFSV: $0 short-term, $0 long-term, 0.00% of NAV; 100% QDI). dimensional.com.
13. Larry Swedroe, “A Tale of 3 Small Value Funds” and “Small Value Funds Not Equal,” etf.com (structured funds, factor loadings, cost per unit of exposure). etf.com.
14. Comparison prompted by @BarbellFactors, X thread on AVUV capacity and BSVO (June 27, 2026). Fund figures are point-in-time and were verified against sponsor fact sheets, prospectuses, and Morningstar; confirm current data before investing.

Disclosure: the author owns AVUV and DFSV, and does not own BSVO. This article is educational and is not financial or tax advice. Fund data changes; expense ratios, AUM, holdings, and distributions should be confirmed with each sponsor before investing.